Advances in treatment of Vogt-Koyanagi-Harada syndrome
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Vogt-Koyanagi-Harada(VKH)syndrome is an autoimmune disease attacking against pigmented cells, resulting in blindness and usually affecting multiple organs including ears, meninges, hair and skin. Correct diagnosis and immediate treatment in the early stage is vital to visual prognosis. Currently, corticosteroids is first-line drug. In addition, VKH patients refractory to corticosteroids can choose other treatment such as immunosuppressive agents and biological agents.

    Reference
    Related
    Cited by
Get Citation

Guo Huang, Pei-Zeng Yang. Advances in treatment of Vogt-Koyanagi-Harada syndrome. Guoji Yanke Zazhi( Int Eye Sci) 2017;17(6):1082-1086

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:March 06,2017
  • Revised:April 21,2017
  • Adopted:
  • Online: May 24,2017
  • Published: